Summary
Camurus AB saw its stock surge 14.3% to SEK 601.5 following the release of its Q2 and H1 2026 interim results. The company reported a new high in product sales and a sizable increase in royalty revenues that offset a small decline in milestone-related income. Management also reaffirmed its full-year 2026 financial targets and provided an update on several development programs and regulatory interactions.
Quarterly performance
For the second quarter, total revenue increased 4% to SEK 702 million. Product sales reached SEK 528 million, representing an all-time quarterly high for the company, while royalty revenue rose 42% to SEK 127 million. Operating profit was broadly unchanged year-on-year at SEK 293 million. Net profit declined marginally to SEK 241 million.
Company commentary highlighted that the lift in royalties largely reflects stronger commercial uptake of treatments for opioid dependence, including Brixadi. The rise in royalty receipts was a decisive factor in the quarter's revenue mix.
Guidance and investor reaction
Management confirmed its guidance for full-year 2026, keeping the revenue range at SEK 2.6 billion to SEK 2.9 billion and operating profit in the band of SEK 900 million to SEK 1.2 billion. That decision to stick with prior targets was interpreted by the market as a stabilising signal following a more volatile previous quarter.
Analysts had entered the reporting period with a generally bullish consensus, and average price targets were positioned well above the stock's trading levels ahead of the news. The quarterly results and the reaffirmed outlook appear to have reduced perceived execution risk, which helped close the gap between the share price and where analysts had been valuing the business.
Pipeline and regulatory developments
The company reported progress on several clinical and regulatory fronts. Camurus said it has responded to the U.S. Food and Drug Administration's outstanding comments tied to a Complete Response Letter for CAM2029 in acromegaly and expects a subsequent regulatory update in the near term. The pivotal Phase 3 SORENTO study in gastroenteropancreatic neuroendocrine tumors is reported to be on track for a primary analysis readout in Q4 2026.
Separately, preparations are underway for a Phase 2b trial of CAM2056, a monthly semaglutide candidate. The program has drawn attention given the competitive environment in weight-loss therapies.
Market context
Broader markets offered a neutral-to-supportive backdrop, with U.S. indices posting modest gains on the day. Within Sweden's pharmaceutical sector, peers including Bonesupport, BioArctic, SOBI and Vitrolife were trading flat to lower. That divergence underscores that Camurus' strong single-session move was driven principally by company-specific results rather than by a sector-wide or macroeconomic shift.
Conclusion
Investors reacted to the combination of record product sales, sharply higher royalties, a reaffirmed full-year forecast and constructive updates on regulatory and clinical milestones. Together these elements provided a rationale for a notable re-rating of the stock, culminating in one of the more pronounced one-day gains for Camurus in recent memory.